OpGen closes on $5 million

Jan. 26, 2005 — OpGen Inc., a Madison, Wis., developer of microfluidics and other technologies for single molecule DNA analysis, announced the closure of a $5 million Series B round of funding.

Mason Wells Biomedical Fund, Stonehenge Capital, The State of Wisconsin Investment Board and the Wisconsin Alumni Research Foundation participated in the round. All were previously investors in the company.

OpGen will use the funds to expand marketing and sales infrastructure, conduct commercial service collaborations and contracts and accelerate commercialization of its technology, according to a company release.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.